Kymera Therapeutics
- Market cap
- 9.01B
- P/E (TTM)i
- -33.34
- P/Bi
- 5.97
- EPSi
- -3.69
- Div yieldi
- 0.00%
- 52W posi
- 71%
Anonymous reader poll. Unscientific, not investment advice.
Kymera Therapeutics shares were changing hands at 108.35, up 2.24% on the day. Its market capitalisation is about 9.01B, the #1580 most valuable US-listed company we track. The 15 analysts covering the stock are, on balance, at Buy, targeting an average of 141.60 (+31%). Against a 52-week band of 55.26-130.05, the shares are currently 71% of the way up.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 8% of the universe, above its 200-day average.
- Signal has read BUY for 6 months.
- Its last 6 Buy calls have actually lost 7% on average three months out - the strategy's edge here has come from the basket, not from this ticker.
- Recent price momentum is +40.6% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 12.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 105.98
- Open
- 104.58
- Day range
- 103.45 - 108.68
- Avg price
- 107.72
- Volume
- 1.17M
- Turnover
- 125.75M
- Turnover ratei
- 1.77%
- Volume ratioi
- 1.26
- Amplitudei
- 4.94%
- 52-week rangei
- 55.26 - 130.05
Valuation
- P/Ei
- -29.36
- P/E (TTM)i
- -33.34
- P/Bi
- 5.97
- EPSi
- -3.69
- Book value / shi
- 18.15
- Net profit
- -306.83M
- Net assets
- 1.51B
Share structure
- Market cap
- 9.01B
- Float capi
- 7.16B
- Shares out
- 83.15M
- Float sharesi
- 66.04M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-08-21
16.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+214.11M net over the window
Short interest
- Shares short
- 10.53M
- % of floati
- 12.66%
- Days to coveri
- 16.13
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Kymera Therapeutics (KYMR)?
Kymera Therapeutics last traded at 108.35. The quote on this page refreshes every few seconds while US markets are open.
What is Kymera Therapeutics's market cap?
About 9.01B.
What is the P/E ratio of Kymera Therapeutics?
The trailing twelve-month P/E is -33.34. The Valuation tab shows it against the stock's own five-year range.
Does Kymera Therapeutics pay a dividend?
Kymera Therapeutics does not currently pay a regular dividend.
Is Kymera Therapeutics a buy according to analysts?
The consensus of 15 analysts is a Buy rating, with an average 12-month price target of 141.60, which implies 30.7% upside from the current price. This is not investment advice.
What is Kymera Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Kymera Therapeutics a B (Buy). Twelve-month momentum in the top 8% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 08:49:16 · For reference only, not investment advice and not tailored to your situation.